BiVACOR develops and manufactures total artificial hearts for patients with end-stage heart failure.

BiVACOR

BiVACOR Inc

BiVACOR® is a clinical-stage medical device company pioneering the development of a long-term therapy for patients with biventricular heart failure. Under the expert direction of its founder and Total Artificial Heart (TAH) inventor, Daniel Timms, PhD, and the guidance of two luminaries in cardiovascular surgery, William E. Cohn, MD, and O.H. (Bud) Frazier, MD, the BiVACOR TAH is currently undergoing an FDA-approved first-in-human Early Feasibility Study (EFS). Headquartered in Huntington Beach, California, with clinical offices in Houston, Texas, and international offices in Gold Coast, Australia, BiVACOR is committed to addressing the global unmet need of patients with end-stage heart failure awaiting transplant by providing the next generation of life-extending solutions.

About the BiVACOR Total Artificial Heart (TAH):
The BiVACOR TAH represents a paradigm shift in artificial heart design. The size of the BiVACOR TAH is suitable for most men and women (Body Surface Area >1.4 m2). Despite its small size, the BiVACOR TAH is capable of providing enough cardiac output for an adult male undergoing exercise. Using magnetic levitation technology, the same principle used in high-speed trains, the product features a unique pump design with a single moving part: a magnetically suspended dual-sided rotor with left and right vanes positioned within two separate pump chambers, forming a double-sided centrifugal impeller that propels blood from the respective pump chambers to the pulmonary (lung) and systemic (body) circulations. The TAH has no valves or flexing ventricle chambers, with MAGLEV making pulsatile outflow possible by rapidly cycling the pump's rotor. The non-contact suspension of the rotor via MAGLEV is designed to eliminate the potential for mechanical wear and provide large blood gaps that minimize blood trauma, offering a durable, reliable, and biocompatible heart replacement.

Medical Research Future Fund (MRFF)

National Institutes of Health

Cormorant Asset Management

OneVentures

Together with The Texas Heart Institute, Baylor College of Medicine, and Texas Medical Center, we have successfully completed the first-in-human implantation of the BiVACOR Total Artificial Heart as part of the U.S. FDA Early Feasibility Study. 

🎙️“I’m incredibly proud to witness the successful first-in-human implant of our TAH. This achievement would not have been possible without the courage of our first patient and their family, the dedication of our team, and our expert collaborators at The Texas Heart Institute. Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” - Daniel Timms, PhD, Founder and Chief Technology Officer of BiVACOR

🎙️“The Texas Heart Institute is enthused about the groundbreaking first implantation of BiVACOR’s TAH. With heart failure remaining a leading cause of mortality globally, the BiVACOR TAH offers a beacon of hope for countless patients awaiting a heart transplant. We are proud to be at the forefront of this medical breakthrough, working alongside the dedicated teams at BiVACOR, Baylor College of Medicine, and Baylor St. Luke’s Medical Center to transform the future of heart failure therapy for this vulnerable population.” - Dr. Joseph G. Rogers, M.D., President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator on the research.

The successful implantation of BiVACOR’s TAH highlights the potential of innovative technologies to address critical challenges in cardiac care, such as long transplantation waitlists. BiVACOR and The Texas Heart Institute remain committed to advancing the field of cardiac medicine and improving outcomes for patients worldwide.

Learn more about today’s announcement in our joint press release: https://lnkd.in/gBTGFqww> 

William Cohn Alexis Shafii  

#HeartFailure #HeartDisease #Cardiology #MedTech

"Utilizing advanced maglev technology, our Total Artificial Heart brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant." - Dr. Daniel Timms, Founder & CTO of BiVACOR 

📰 CyberGuy , Kurt Knutsson
https://lnkd.in/ep2fSgVf

The first patient received the BiVACOR Total Artificial Heart (TAH) implant on July 9 as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). On July 17, eight days following the BiVACOR TAH implant, a donor heart became available and was transplanted into the patient, removing the BiVACOR TAH and meeting a goal of the EFS to evaluate the safety and performance of the BiVACOR TAH as a bridge-to-heart-transplant solution for patients living with severe biventricular heart failure or univentricular heart failure in which left ventricular assist device support is not recommended.

The Texas Heart Institute

📰 ScienceAlert, Carly Cassella
https://lnkd.in/g48-izrc

The successful implantation of the BiVACOR Total Artificial Heart marks a new era in cardiac care, offering hope to thousands of patients awaiting heart transplants.

📰 ABC News, Good Morning America
https://lnkd.in/gvXaCxPx

“We anticipate the BiVACOR Total Artificial Heart may eventually save numerous lives, as well as improve the quality of life for patients who otherwise have no alternative therapy available.” - Dr. Alexis Shafii, Surgical Director of Heart Transplantation at Baylor St. Luke’s Medical Center and Associate Professor of Surgery, Cardiothoracic Transplant & Circulatory Support at Baylor College of Medicine

🤝 The Texas Heart Institute, St. Luke's Health, Baylor College of Medicine

📰 IGN Entertainment, Anthony Wood
https://lnkd.in/dhJafKjH

"I would be remiss without calling out the patient and his family for their bravery and commitment to advancing this field. It takes an incredibly thoughtful, courageous person to say, “I’ll be the first to have my heart removed and have a mechanical device put in.”

He has our admiration for his willingness to listen to the story and take that first step. He’s opened the door for a lot of people across the world who may not have access to a viable potentially long-term option for a device."

- Joseph G. Rogers, M.D., President and CEO of The Texas Heart Institute and National Principal Investigator

📰Healio, Scott Buzby

https://lnkd.in/gqua55Qh

“The first thing [the patient] said when the breathing tube came out was: ‘I feel great,’” Rogers told Healthcare Brew.

Seven days after the surgery, the patient walked about one-tenth of a mile, according to an emailed statement. While active, the titanium heart pumped 12 liters of blood flow per minute, which is similar to a human heart’s capabilities.

The Texas Heart Institute
Joseph G. Rogers, M.D.

https://lnkd.in/gEqt6eax

📰 Morning Brew, Healthcare Brew, Cassie McGrath

“This is an amazing advancement as the BiVACOR Total Artificial Heart (TAH) may offer hope for countless patients who suffer from end-stage heart failure. This device may serve as a life-saving bridge to a heart transplant; future studies may prove its potential as a long-term pump that can effectively serve as a total replacement for a patient’s heart. We anticipate the BiVACOR TAH may eventually save numerous lives, as well as improve the quality of life for patients who otherwise have no alternative therapy available.” - Dr. Alexis Shafii, Surgical Director of Heart Transplantation at Baylor St. Luke’s Medical Center and Associate Professor of Surgery, Cardiothoracic Transplant & Circulatory Support at Baylor College of Medicine

The Texas Heart Institute
St. Luke's Health

📰 The Independent Vishwam Sankaran (they/them)
https://lnkd.in/gkvCTcxQ

“It is rewarding to see this result and have the BiVACOR Total Artificial Heart (TAH) perform as expected. This successful outcome is a testament to the years of dedication and innovation invested in this project. The patient continues to do well through their recovery, demonstrating the potential impact of the BiVACOR TAH on the future of heart failure treatment.” - Joseph G. Rogers, M.D., President and Chief Executive Officer of The Texas Heart Institute and National Principal Investigator of the research.

📸 The Texas Heart Institute
📰 The Sydney Morning Herald, amanda hooton
https://lnkd.in/g99Kibfg

#cardiology #heartfailure #heartdisease #medicaldevice #medtech

The BiVACOR Total Artificial Heart (TAH) represents a paradigm shift in artificial heart design. 

📏 The size of the BiVACOR TAH is suitable for most men and women (Body Surface Area >1.4 m2). Despite its small size, the BiVACOR TAH is capable of providing enough cardiac output for an adult male undergoing exercise. 

🚅 Using magnetic levitation technology, the same principle used in high-speed trains, the product features a unique pump design with a single moving part: a magnetically suspended dual-sided rotor with left and right vanes positioned within two separate pump chambers, forming a double-sided centrifugal impeller that propels blood from the respective pump chambers to the pulmonary (lung) and systemic (body) circulations. 

❤️ The TAH has no valves or flexing ventricle chambers, with MAGLEV making pulsatile outflow possible by rapidly cycling the pump's rotor. The non-contact suspension of the rotor via MAGLEV is designed to eliminate the potential for mechanical wear and provide large blood gaps that minimize blood trauma, offering a durable, reliable, and biocompatible heart replacement.

🎙️"Utilizing advanced MAGLEV technology, our TAH brings us one step closer to providing a desperately needed option for people with end-stage heart failure who require support while waiting for a heart transplant. I look forward to continuing the next phase of our clinical trial.” - Daniel Timms, Founder & CTO of BiVACOR

📰 Interesting Engineering
https://lnkd.in/gETGEM_A

#heartfailure #heartdisease #cardiology #medicaldevice #medtech

Mobile Non Scaleable Content

CrUX Dataset

Cloudflare JS

CDN JS

CrUX Top 50m

Facebook Sharer

Microsoft

Pinterest

DigiCert SSL

WhatsApp

Founder/CTO

Daniel Timms

Chief Executive Officer

Thomas Vassiliades

Director, RA/QA

Dawnel Scott

Senior Electrical Engineer

Matthias Kleinheyer

Business Management

Jeannie Joughin PhD, MAICD

Controller

Lindsey Brede

Supply Chain Manager

Nathan Kong

Quality Assurance Manager

Valeri Davila

Engineering

Abs Bahour

Independent Consultant

Chetan Panwala

Jim Dillon

Founder and CTO

Chief Executive Officer and President

John Fraser

Chief Medical Officer, and Co-Founder

Chief Medical Officer and Co-Founder

William E Cohn

Chief Medical Officer & Board of Directors

United States Medical Device Companies with Early Stage Venture Funding

Medical Device Companies With Less Than $1B in Revenue (Top 10K)

United States Companies With Less Than $500M in Revenue (Top 10K)

Hedge Fund Funded Companies

BiVACOR is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives who are diligently working to advance this ground-breaking technology. Together, they have established a strong collaborative network that extends both nationally and internationally. Their world headquarters are located in Houston, Texas, USA, and their international office is in Brisbane, Australia.

Grant - BiVACOR

Series B - BiVACOR

Venture Round - BiVACOR

Houston

Texas

United States

North America

BiVacor reports first human implant of artificial heart

First patient successfully implanted with BiVACOR’s artificial heart

First-in-Human Implantation Of BiVACOR's Total Artificial Heart

The Texas Heart Institute Implants BiVACOR® Total Artificial Heart

BiVACOR wins IDE to start first-in-human study for artificial heart

The artificial heart set to transform medicine – and the Aussie who invented it

Raymond Cohen Named BiVACOR Board Chair

BiVACOR® Receives $13 Million to Support Clinical Trials for the Company's Total Artificial Heart

BiVacor raises $13M to support artificial heart trial

Australian Government announces A$50m investment towards artificial heart development

news impact assignment basic	general	Sep 4, 2024 5:00 AM	a3bf9316
public peers	general	Sep 2, 2024 5:39 AM	56bac013
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Sep 3, 2024 4:48 AM	17439a7f
company summary	general
signals	general
crunchbase trigger	general	Nov 4, 2024 10:53 AM	09208363
crunchbase profile	general	Nov 4, 2024 11:40 AM	75297305
li profile	general	Sep 2, 2024 5:39 AM	fc2348d4
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	d9a10375
peers	general	Sep 2, 2024 5:39 AM	499a3818
news basic	general	Sep 2, 2024 5:39 AM	b6a3d90d
bundesanzeiger	filings
financials download nd	financials
private financials	financials

BIVA

COM:BIVACOR

BiVACOR